
Aquinnah Pharmaceuticals Inc Profile last edited on: 8/26/2019
CAGE: 7ADK1
UEI: T6T9BUCQMDB1
Business Identifier: Therapies to slow progression of ALS and other neurodegenerative diseases Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 07
County: Middlesex
Congr. District: 07
County: Middlesex
Public Profile
Aquinnah Pharmaceuticals is more recently shifted focused to a new area of research (for them) modulationof neurodegenerative stress granules, believed to be important in the pathology of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs disease. The firm is developing therapies to slow the progression of ALS and other neurodegenerative diseases to include, most recently, Alzheimers. Building on the work of founder Ben Wolozin, MD, PhD, 2013 recipient of the prestigious Zenith Fellows Award and chairman of the National Institutes of Health Cellular and Molecular Biology Neurodegeneration Study Section, the firm's drug-screening assays have identified excellent drug candidates with the potential to prevent and possibly reverse the formation of pathological stress granules.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2024 | 2 | NIH | $3,877,726 | |
Project Title: TAU/TIA1 Aggregation Inhibitors for the Treatment of Ad | ||||
2019 | 2 | NIH | $4,117,234 | |
Project Title: TDP-43 Aggregation Inhibitors for the Treatment of ALS |
Key People / Management
Glenn Larsen -- Co-founder, President & CEO
Duane Burnett -- Vice President Medicinal Chemistry
Bob Carpenter
Daniel Geffken -- Chief Financial Officer
Joseph Vacca -- Acting Head Of Chemistry
Travis T Wager -- Vice President, Research
Manfred Weigele -- Co-Founder, Chemistry
Benjamin Wolozin -- Co-Founder, CSO
Duane Burnett -- Vice President Medicinal Chemistry
Bob Carpenter
Daniel Geffken -- Chief Financial Officer
Joseph Vacca -- Acting Head Of Chemistry
Travis T Wager -- Vice President, Research
Manfred Weigele -- Co-Founder, Chemistry
Benjamin Wolozin -- Co-Founder, CSO
Company News
There are no news available.